| scholarly article | Q13442814 |
| P2093 | author name string | Eugenia Jorrín | |
| Ivonne Chon | |||
| Jorge Juan Marinello | |||
| José Alert | |||
| Maria Teresa Solomon | |||
| Nederlay Miranda | |||
| Patricia Lorenzo-Luaces | |||
| Tania Crombet | |||
| P2860 | cites work | Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation | Q27656338 |
| Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer | Q28289291 | ||
| Advances and challenges in the treatment of glioblastoma: a clinician's perspective | Q30620774 | ||
| Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity | Q34426559 | ||
| Current status of local therapy in malignant gliomas--a clinical review of three selected approaches. | Q34733023 | ||
| Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial | Q34778047 | ||
| Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma | Q35914541 | ||
| Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe | Q36248579 | ||
| Epidermal growth factor receptor targeting in cancer | Q36557269 | ||
| Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials | Q36771292 | ||
| A view on EGFR-targeted therapies from the oncogene-addiction perspective. | Q36795486 | ||
| The role of surgery in high-grade glioma--is surgical resection justified? A review of the current knowledge. | Q36840671 | ||
| Bevacizumab for the treatment of glioblastoma. | Q36929502 | ||
| EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects | Q37132708 | ||
| Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies | Q37141964 | ||
| The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms | Q37550601 | ||
| Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer. | Q37631096 | ||
| Cardiovascular effects of EGFR (epidermal growth factor receptor) monoclonal antibodies | Q37743550 | ||
| Epidermal growth factor receptor targeted therapies for solid tumours | Q37864295 | ||
| Risk of anti-EGFR monoclonal antibody-related hypomagnesemia: systematic review and pooled analysis of randomized studies | Q37917796 | ||
| Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT. | Q37996214 | ||
| Nimotuzumab treatment of malignant gliomas | Q38050155 | ||
| Promising new molecular targeted therapies in head and neck cancer | Q38084617 | ||
| Role of targeted agents in metastatic colorectal cancer. | Q38104294 | ||
| Role of radiotherapy for high grade gliomas management | Q38107084 | ||
| Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. | Q38129588 | ||
| Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review | Q38139811 | ||
| Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile | Q39621039 | ||
| Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck | Q40359415 | ||
| Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials | Q44801516 | ||
| Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation | Q44907727 | ||
| Molecular analysis of the erbB gene family calmodulin-binding and calmodulin-like domains in astrocytic gliomas | Q45113694 | ||
| Conditional survival of high-grade glioma in Los Angeles County during the year 1990-2000. | Q46365729 | ||
| Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials | Q48286137 | ||
| A new monoclonal antibody for detection of EGF-receptors in western blots and paraffin-embedded tissue sections | Q67557093 | ||
| Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody | Q74802802 | ||
| Nimotuzumab: evidence of clinical benefit without rash | Q81402511 | ||
| Retrospective evaluation of cetuximab-related adverse events from claims databases--methodological concerns | Q84531667 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 504-509 | |
| P577 | publication date | 2014-02-12 | |
| P1433 | published in | Cancer Biology and Therapy | Q2544651 |
| P1476 | title | Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience | |
| P478 | volume | 15 |
| Q30870633 | Advances in the management of paediatric high-grade glioma |
| Q38214511 | Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer |
| Q90448649 | Clinical outcome and molecular characterization of pediatric glioblastoma treated with postoperative radiotherapy with concurrent and adjuvant temozolomide: a single institutional study of 66 children |
| Q39013294 | Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain |
| Q52365121 | Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. |
| Q91756572 | Efficacy and safety of nimotuzumab in addition to radiotherapy and temozolomide for cerebral glioblastoma: a phase II multicenter clinical trial |
| Q38516823 | Glioblastoma antigen discovery--foundations for immunotherapy. |
| Q37269328 | Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis |
| Q35491503 | Profile of nimotuzumab in the treatment of high-grade glioma |
| Q55458447 | Reported outcomes of children with newly diagnosed high-grade gliomas treated with nimotuzumab and irinotecan. |
| Q39004424 | Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors |
| Q54942652 | Trends in Malignant Glioma Monoclonal Antibody Therapy. |
Search more.